

เอกสารอ้างอิง Bilberry

1. Moyer RA, Hummer KM, Finn CE, Frei B, Wrolstad RE. Anthocyanins, phenolics and antioxidant capacity in diverse small fruits: *Vaccinium*, *Rubus* and *Ribes*. J Agric Food Chem 2002; 50:519-25.
2. Ames BN. Dietary carcinogen and anticarcinogens. Science 1983; 221:1256-63.
3. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants and degenerative disease of aging. Proc Natl Acad Sci US.A. 1993; 90:7915-22.
4. Anonymous, Monograph: *Vaccinium myrtillus* (Bilberry). Altern Med Rev 2001; 6:500-4.
5. ริดเดอร์ส ไคเจสท์, กลุ่มมือตลาดใช้ วิตามิน แร่ธาตุและสมุนไพร. บริษัทริดเดอร์สไคเจสท์ (ประเทศไทย) จำกัด: กรุงเทพฯ, 2548: 108-9.
6. Grieve M. *A Modern Herbal*. New York, NY: Dover Publications 1971; 1:386-6.
7. Caselli L, Clinical and electroretinographic study on activity of anthocyanosides. Arch Med Int 1985; 37:29-35.
8. Baj A, Bombardelli E, Gabetta B, Martinelli EM. Qualitative and quantitative evaluation of *Vaccinium myrtillus* anthocyanins by high-performance liquid chromatography. J Chromatography 1983; 279:365-72.
9. Morazzoni P, Bombardelli E. *Vaccinium myrtillus* I. Fitoterapia 1996; 67:3-29.
10. Hakkien SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 1999; 47:2274-9.
11. Ichianagi T, Hatano Y, Matsugo S, Konishi T. Structural dependence of HPLC separation pattern of anthocyanins from bilberry (*Vaccinium myrtillus* L.) Chem Pharm Bull 2004; 52:628-30.
12. Latti AK, Riihinen KR, Kanulainem PS. Analysis of anthocyanin variation in wild population of bilberry (*Vaccinium myrtillus* L.) in Finland. J Agric Food Chem 2008; 56:190-6.
13. Zhang Z, Kou X, Fugal K, McLaughlin J. Comparison of HPLC methods for determination of anthocyanins and anthocyanidins in bilberry extracts. J Agric Food Chem 2004; 52:688-91
14. Burdulis D, Ivanauskas L, Dirse V, Kazlauskas S, Razukas A. Study of diversity of anthocyanin composition in bilberry (*Vaccinium myrtillus* L) fruits. Medicina (Kaunas) 2007; 43:971-7.

15. Burdulis D, Ivanauskas L, Jakstas V, Janulis V. Analysis of anthocyanins content in bilberry (*Vaccinium myrtillus* L) fruit crudl drug by high-performance liquid chromatography method *Medicina* (Kaunas) 2007; 43:568-74.
16. Das DK, Maulik N. Resveratrol, in cardioprotection: a therapeutic promise of alternative medicine. *Mol Interv* 2006; 6:36-47.
17. Hattori R, Otani H, Maulik N and Das DK. Pharmacoligical preconditioning with resveratrol: role of nitric oxide. *Am J Physiol Heart Circ Physiol* 2002; 282:H1988-H1995.
18. Das S, Cordis CA, Maulik N and Das DK. Pharmacological preconditioning with resveratrol: a role of CREB-dependent Bcl-2 signal via adenosine A₃ receptor activation. *Am J Physiol Heart Circ Physiol* 2005; 288:H328-H335.
19. Pezzuto JM. Plant-derived anticancer agents. *Biochem Pharmacol* 1999; 53:121-33.
20. Yen GC, Duh PD, Lin CW. Effect of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. *Free Radic Res* 2003; 37:509-14.
21. Losa GA. Resveratrol modulate apoptosis and oxidation in human blood mononuclear cells. *Eur J Clin Invest* 2003; 33:818-23.
22. Bagchi D, Das DK, Tosaki A, Bagchi M, Kothari SC. Benefit of resveratrol in women's health. *Drug Expt Clin Res* 2001; 27:233-48.
23. Lyons MM, Chengwoo Y, Toma RB et al. Resveratrol in raw and baked blueberries and bilberries. *J Agric Food Chem* 2003; 51:5867-70.
24. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR. HPLC method for screening of flavonoids and phenolic acids in berries. *J Sci Food Agric* 1998; 77:543-51.
25. Dixon RA, Paiva NL. Stress induced phenylpropanoid metabolism. *Plant Cell* 1995; 7:1085-97.
26. Giusti M M. Abstract of Papers, 226th ACS National Meeting, New York, United States, September 7 – 11,2003. Anthocyanin rich extracts and their potential chemo-preventive effects. *AN* 2003:629435 [Copyright (C) 2008 ACS on SciFinder (R)]
27. Zhao C, Monica Giusti M, Malik M, Moyer M P, Magnuson B A. Effects of commercial anthocyanin-rich extracts on colonic cancer and nontumorigenic colon cell growth. *J Agric Food Chem* 2004;52:6122-8.

28. Wu Q K, Koponem J M, Mykkaenem H M, Toerroenen A R. Berry phenolic extracts modulates the expression of p21WAF1 and Bdx but not Bcl-2 in HT-29 colon cancer cells. *J Agric Food Chem* 2007;55:1156-63.
29. Cooke D, Schwarz M, Boocock D et al. Effect of cyaniding-3-glucoside and an anthocyanin mixture from bilberry on adenoma development in the ApcMin mouse model of intestinal carcinogenesis relationship with tissue anthocyanin levels. *Intern J Cancer* 2006;119:2213-20.
30. Roy S, Khanna S, Alessio H M et al. Anti-angiogenic property of edible berries. *Free Radical Res* 2002;36:1023-31.
31. Bagchi M, Zafra-Stone S, Losso J N, Sen C K, Roy S, Harra S, Bagchi D. Role of edible berry anthocyanins in angiogenesis. *Natraceu Sci Technol* 2007;6:527-48.
32. Choi E H, Ok H E, Yoon Y, Magnuson B A, Kim M K, Chun H S. Protective effect of anthocyanin-rich extract from bilberry (AREB) (*Vaccinium myrtillus* L.) against myelotoxicity induced by 5-fluorouracil. *Biofactor* 2007;27:55-65.
33. Kristen G. Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. *J Applied Physio* 2006;100:1164-70.
34. Allen FM. Blueberry leaf extract. Physiologic and clinical properties in relation to carbohydrate metabolism. *JAMA* 1927;89:1577-81.
35. Bever B, Zahnd G. Plants with Oral hypoglycemic action. *Quart J Crude Drug Res* 1979;19:139-96.
36. Bradamante S, Barenghi L, Piccinini F, et al. Resveratrol provider late-phase cardioprotection by means of nitric oxide and adenosine-mediated mechanism. *Eur J Pharmacol* 2003;465:115-23.
37. Liu Z, Seng Y, Zhang X et al. Effects of *trans*-resveratrol on hypertension induced cardiac hypertrophy using the partially nephrotomized rat model. *Clin Expt Pharmacol Physiol* 2005;32:1049-54.
38. Yang Y, Yang J, Jeng Y, Chang M, Ni Y. Prevalence and rapid identification of clarithromycin resistant *Helicobacter pylori* isolates in children. *Pediatr Infect Dis J* 2001;20:662-6.
39. Moss SF. The carcinogenic effect of *H. pylori* on the gastric epithelial cell. *J Physiol Pharmacol* 1999;50:847-56.

40. Burger Q, Weiss E, Sharm N, et al. Inhibition of *Helicobacter pylori* adhesion to human gastric mucus by a high molecular weight constituent of cranberry juice. *Crit Rev Food Sci Nutr* 2002;42:279-84.
41. Chatterjee A, Yasmin T, Bagchi D, Stohs S J. Inhibition of *Helicobacter pylori* *in vitro* by various berry extracts, with enhanced susceptibility to clarithromycin. *Molecular Cell Biochem* 2004;265:19-26.
42. Wegmann R, Meada K, Tronch P, Bastide P. Effects of anthocyanosides on photoreceptors. Cytoenzymatic aspect. *Ann Histochem* 1969; 14:237-56.
43. Jayle GE, Aubert L. Action des glucosides d' anthocyanes sur la vision scotopique et mesopique du sujet normal. *Therapie* 1964;19:171-85. [Article in French]
44. Terrasse J, Moinade S. Premiers resultants obtenus avec un nouveau facteur vitaminique P "les anthocyanosides" extraits du *Vaccinium myrtillus*. *Presse Med* 1964;72:397-400. [Article in French]
45. Canter PH , Ernst E. Anthocyanosides of *Vaccinium myrtillus* (Bilberry) for night vision – a systemic review of placebo – controlled trials. *Survey Ophthalmol* 2004; 49:38-50.
46. Marmor MF , Zrenner E. Standard for clinical electro-retinography (for the International Social for Clinical Electrophysiology of Vision) *Doc Ophthalmol* 1995 ; 89 : 199–210 .
47. Jayle GE , Aubry M , Gavini H et al . Etude concernant l' action sur la vision nocturne des anthocyanosides extrait du *Vaccinium myrtillus* . *Ann Ocul* 1965 ; 198 : 556–62 .
48. Alfieri R. Sole P. Influence des anthocyanosides administres par voie or – perlinguale sur l' adapto – electroretinogramme (AERG) en lumiere rouge chez l' home. *Soc Biol Clermont – Ferrand* 1996 ; 160 : 1590–3 .
49. Magnasco A, Zongirian M. Influenza degli antocianosidi sulla soglia retinica differenziale mesopica [Influence of anthocyanosides on the mesopic differential threshold of the retina] *Ann Ottalmol Clin Ocul* 1966 ; 92 : 188–93 .
50. Belleoud L , Leluan D , Boyer Y. Etude des effets des glucoside d' anthocyane sur la vision nocturne du personnel Navigant . *Rev Med Averonaut Spat* 1967 ; 6 : 5–10 .
51. Ponte F , Lauricella M. Effect of *Vaccinium myrtillus* total extract on the recovery in the dark of the human electroretinogram. *Atti VII Simposio ISCERG , Istambul* 1969 : 355–66 .
52. Sala D , Rossi PL , Rolando SD et al . Effetto degli antocianosidi sulle "performances" visic alle basse luminanze . *Minerva Oftalmol* 1979 ; 21 : 283–5 .

53. Sbrozzi F , Landini J , Zango M. Night vision affected by anthocyanosides . An electroretinographic test . *Minerva Oftalmol* 1983 ; 24 : 189–93 .
54. Levy Y , Glovinsky Y. The effect of anthocyanosides on night vision. *Eye* 1998 ; 12: 967– 9.
55. Muth E Laurent J , Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity . *Altern Med Rev* 2000 ; 5 : 164–73 .
56. Zadok D , Levy Y , Glovinsky . The effect of anthocyanosides in a multiple oral dose on night vision . *Eye* 1999 ; 13 : 743–6 .
57. Bravetti G. Preventive medical treatment of senile cataract with vitamin E and anthocyanosides: clinical evaluation. *Ann Ottalmol Clin Ocul* 1989;115:109. [Article in Italian]
58. Harvsteen B. Flavonoids, a class of natural products of high pharmacological potency. *Biochem Pharmacol* 1983; 32:1141-48.
59. Gabor M. Pharmacologic effects of flavonoids on blood vessels. *Angiologica* 1972; 9:355-74.
60. Mian E, Curri SB, Lietti A, Bombardelli E. Anthocyanosides and the walls of the microvessels: further aspects of the mechanism of action of their protective effect in syndromes due to abnormal capillary fragility. *Minerva Med* 1977; 68:3565-81.
61. Antignani P L, Caliumi C. Medical treatment of chronic venous insufficiency. *Vascular Dis Pre* 2007;4:117-24.
62. Scharrer A, Ober M. Anthocyanosides in the treatment of retinopathies. *Klin Monatsbl Augenheilkd* 1981;178:386-9. [Article in German]
63. Martin-Aragon S, Basabe B, Benedi J M, Villar A M. Antioxidant action of *Vaccinium myrtillus* L. *Phytotherapy Rearch* 1998;12 (suppl 1, Second International Symposium on Natural Drugs, 1997):S104-6.
64. Blumberg Jeffrey M. Bilberry (*Vaccinium myrtillus*) anthocyanins modulate heme oxygenase-1 and glutathione S-transferase-pi expression in ARPE-19 cells. *Investigative Ophthalmol & Visual Sci* 2007; 48:2343-9.
65. Chaundry PS, Cambera J, Juliana HR, Varma SD. Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. *Biochem Pharmacol* 1983;32:1995-8.
66. Varma SD, Mizuno A, Kinoshita JH. Diabetic cataracts and flavonoids. *Science* 1977;195:87-9.

67. Perossini M, et al. Diabetic and hypertensive retinopathy therapy with *Vaccinium myrtillus* anthocyanosides (Tegens): Double-blind placebo controlled clinical trial. *Ann Ottalmol Clin Ocul* 1987;113:1173. [Article in Italian]
68. Magistretti MJ, Conti M, Cristoni A. Antiulcer activity of anthocyanidin from *Vaccinium myrtillus*. *Arzneim Forsch* 1988;38:686-90.
69. Rao CN, Rao VH, Steinman B. Influence of bioflavonoids on the collagen metabolism in rats with adjuvant induced arthritis. *Ital J Biochem* 1981;30:54-62.
70. Laplaud PM, Lelubre A, Chapman MJ. Antioxidant action of *Vaccinium myrtillus* extract on human low density lipoproteins *in vitro*: initial observation. *Fundam Clin Pharmacol* 1997;11:35-40.
71. Bottecchia D, et al. Preliminary reports on the inhibitory effect of *Vaccinium myrtillus* anthocyanosides on platelet aggregation and clot retraction. *Fitoterapia* 1987;48:3-8.
72. Puilleiro G, et al. *Ex vivo* study of the inhibitory effects of *Vaccinium myrtillus* anthocyanosides on human platelet aggregation. *Fitoterapia* 1989;60:69-75.
73. Colombo D, Vescovini R. Controlled trial of anthocyanosides from *Vaccinium myrtillus* in primary dysmenorrhea. *G Ital Ost Ginecol* 1985;7:1033-1038.
74. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines, 2nd ed., Medical Economics Co, Montvale; NY., 2000.
75. Abebe W Herbal medication : potential for adverse interactions with analgesic drugs. *J Clin Pharm Therap* 2002 ; 27 : 391– 401 .
76. Morazzoni P, Bombardelli E. *Vaccinium myrtillus* L. *Fitoterapia* 1996 ; 67 : 3 –29 .

เอกสารอ้างอิง

ชา กับ การ ดู สาร ชีวะ สาร ใน ชา

1. Khan N, Mukhtar H. Tea polyphenols for promotion. *Life Sci* 2007;81(7): 519-33.
2. Cook JD. Adaptation in iron metabolism. *Am J Clin Nutr* 1990;51:301-8.
3. Hallberg L, Brunes M, Erlandsson M, Sandberg AS, Rossander Hulten L. Calcium: effect of different amounts on non-haem and haem-iron absorption in man. *Am J Clin Nutr* 1991;53: 112-9.
4. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by phenolic-containing beverages. *Br J Nutr* 1999; 81: 289-95
5. Brune M, Rossander L, Hallberg L. Iron absorption and phenolic compounds: importance of different phenolic structures. *Eur J Clin Nutr* 1989;43:547-58.
6. Tuntawiroon M, Sritongkul N, Brune M, et al. Dose-dependent inhibitory effect of phenolic compounds in foods on nonhaem-iron absorption in men. *Am J Clin Nutr* 1991;53: 554-7.
7. Zijp IM, Korver O, Tijburg LBM. Effect of tea and other dietary factors on iron absorption. *Crit Rev Food Sci Nutr* 2000;40(5): 371-98.
8. Nelson M, Poulter J. Impact of tea drinking on iron status in the UK: a review. *J Hum Nutr Diet* 2004;17(1): 43-54.
9. Thephinlap C, Ounjaijean S, Khansuwan U, Fucharoen S, Porter JB, Srichairatanakool S. Epigallocatechin-3-gallate and epicatechin-3-gallate from greentea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress. *Med Chem* 2007;3(3): 2898-96.
10. Zhang D, Hendricks DG, Mahoney AW, Yu Y. Effect of tea on dietary iron bioavailability in anemic and healthy rats. *Nutr Report Inter* 1988;37(6): 1225-35.

11. Hamdaoui M, Hedhili A, Doghri T, Tritar B. Effect of tea on iron absorption from the typical Tunisian meal couscous fed to healthy rats. *Ann Nutr Metab* 1994;38(4): 226-31.
12. Hamdaoui MH, Chahed A, Ellouze-Chabchoub S, Marouani N, Ben Abid Z, Hedhili A. Effect of green tea decoction on long-term iron, zinc and selenium status of rats. *Ann Nutr Metab* 2005;49(2): 118-24.
13. Fairweather-Tait SJ, Piper Z, Fatemi S, Jemil A, Moore GR. The effect of tea on iron and aluminium metabolism in the rat. *Br J Nutr* 1991;65(1): 61-8.
14. Anon. The influence of tea on iron and aluminium bioavailability in the rat. *Nutr Rev* 1991;49(9): 287-9.
15. Record IR, McInerney, JK, Dreosli IE. Black tea, green tea, and tea polyphenols: effects on trace element status in weanling rats. *Biol Trace Elem Res* 1996;53(1-3): 27-43.
16. Kim HS, Miller DD. Proline-rich proteins moderate the inhibitory effects of tea on iron absorption in rats. *J Nutr* 2005; 135:532-7
17. South PK, House WA, Miller DD. Tea consumption does not affect iron absorption in rats unless tea and iron are consumed together. *Nutr Res* 1997;17(8):1303-10.
18. Yeung CK, Zhu L, Glahn RP, Miller DD. Tissue iron distribution and adaptation of iron absorption in rats exposed to a high dietary level of NaFeEDTA. *J Agri Food Chem* 2005; 53(20): 8087-91.
19. Alemdaroglu NC, Wolfram S, Boissel JP, Closs E, Spahn-Langguth H, Langguth P. Inhibition of folic acid uptake by catechins and tea extracts in Caco-2 cells. *Planta Med* 2007;73(1): 27-32.
20. Brown RC, Kline A, Simmons WK, Hurrell RF. The influence of Jamaican herb teas and other polyphenol-containing beverages on iron absorption in the rat. *Nutr Res* 1990;10(3): 343-53.
21. Lu Y, Bennick A. Interaction of tannin with human salivary proline-rich proteins. *Arch Oral Biol* 1998;43: 717-28.

22. Massie HR, Aiello VR, et al. Inhibition of iron absorption prolongs the life span of *Drosophila*. *Mech Ageing Dev* 1993;67(3): 227-37.
23. Disler PB, Lynch SR, Charlton RW, et. al. The effect of tea on iron absorption. *Gut* 1975;16: 193-200.
24. Alarcon PD, Donovan ME, Forbes GB, Landaw SA, Stockman JA. Iron absorption in the thalassemia syndromes and its inhibition by tea. *New Eng J Med* 1979;300(5-8):
25. Samman S, Sandstrom B, Toft MB, Bukhave K, Jensen M, Sorensen M. Green tea and rosemary extract added to foods reduces non-haem iron absorption. *Am J Clin Nutr* 2001; 73(3): 607-12.
26. Hurrell FR, Reddy M, Cook JD. Inhibition of iron absorption in man by polyphenolic containing beverages. *Br J Nutr* 1999;81: 289-95.
27. Ullmann U, Haller J, Bakker GCM, Brink EJ, Weber P. Epigallocatechin gallate (EGCG) (TEAVIGO™) does not impair non-haem-iron absorption in man. *Phytomed* 2005;12: 410-5.
28. Gardner EJ, Ruxton CH, Leeds AR. Black tea-helpful or harmful? A review of the evidence. *Eur J Clin Nutr* 2007;61(1): 3-18.
29. Merhav H, Amitai Y, Palti H, Godfrey S. Tea drinking and microcytic anemia in infants. *Am J Clin Nutr* 1985;41(6): 1210-3.
30. Tympa-Psirropoulou E, Vagenas C, Psirropoulou D, Dafni O, Matala A, Skopouli F. Nutritional risk factors for iron-deficiency anaemia in children 12-24 months old in the area of Thessalia in Greece. *Int J Food Sci Nutr* 2005;;56(1): 1-12.
31. Metha SW, Pritchard ME, Stegman C. Contribution of coffee and tea to anemia among NHANES II participants. *Nutr Res* 1992;12 :209-22.

32. Gabrielle GB, De Sandre G. Excessive tea consumption can inhibit the efficacy of oral iron treatment in iron-deficiency anemia. *Haematologica* 1995;80(6): 518-20.

33. Kogirima M, Nishino K, Kakuda T, Suzuki Y, Imaki M, Nishimura K. Nippon Eiyo Shokuryo Gakkaishi 2001;54(2): 81-7.

34. Toshiro M, Kazuyo M, Takuro S, et al. The influence of tea on iron absorption from controlled release product. *J Nippon Hosp Pharm Assoc* 12(6): 411-4.

35. Mitamura T, Kitazono M, Yoshimura O, Yakushiji M. The influence of greentea upon the improvement of iron deficiency anemia with pregnancy treated by sodium ferrous citrate. *Nippon Sanka Fujinka Hakkai Zasshi* 1989;41(6): 688-94.

36. Kubota K, Sakura T, Nakazato K, Morita T. Effect of green tea on iron absorption in elderly patients with iron deficiency anemia. *Japan J Ger* 1990;27(5): 555-8.

37. Hunt JR, Roughead ZK. Adaptation of iron absorption in men consuming diets with high or low iron bioavailability. *Am J Clin Nutr* 2000; 71: 94-102.